Increasing n-3 PUFA levels linked to risk of atrial fibrillation in the OMEMI trial

The OMEMI (Omega-3 Fatty acids in Elderly with Myocardial Infarction) trial was performed by several members of the network. In the trial, elderly patients with a recent myocardial infarction were randomized to 1.8 g/day of n-3 polyunsaturated fatty acids (n-3 PUFAs) or control (corn oil) for 2 years. No effect on major cardiovascular events (MACE) was demonstrated, however there were numerically more incident atrial fibrillation in the n-3 PUFA arm. In a recently published secondary analysis, greater on-treatment increases in eicosapentaenoic acid (EPA) were associated with lower risk of MACE and higher risk of atrial fibrillation. This is in line with other recent reports, indicating that n-3 PUFA supplementation may increase the risk of atrial fibrillation. Read more at

Categories: NEWS

%d bloggers like this: